reports
- Adrian Pehl
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
BEN BENETEAU SA
TPE PVA TEPLA AG
TRI TRIGANO SA
MBB MBB INDUSTRIES SE
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
SIX2 SIXT SE
CWC CEWE STIFTUNG & CO KGAA
SEM SEMPERIT HOLDING AG
DLG DE'LONGHI S.P.A.
PAT PATRIZIA AG
JEN JENOPTIK AG
CLA CLARANOVA SE
KTA KNAUS TABBERT
DEME DEME GROUP NV
TUI TUI AG
SHUR SHURGARD SELF STORAGE LIMITED
R3NK RENK GROUP AG
HBX HBX GROUP INTERNATIONAL PLC
- Adrian Pehl
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
BEN BENETEAU SA
TPE PVA TEPLA AG
TRI TRIGANO SA
MBB MBB INDUSTRIES SE
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
SIX2 SIXT SE
CWC CEWE STIFTUNG & CO KGAA
SEM SEMPERIT HOLDING AG
DLG DE'LONGHI S.P.A.
PAT PATRIZIA AG
JEN JENOPTIK AG
CLA CLARANOVA SE
KTA KNAUS TABBERT
DEME DEME GROUP NV
TUI TUI AG
SHUR SHURGARD SELF STORAGE LIMITED
R3NK RENK GROUP AG
HBX HBX GROUP INTERNATIONAL PLC
- Christophe Chaput
- Christophe Chaput
Pharming Group reports first quarter 2025 financial results and provid...
Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adju...
Pharming Group announces the 2025 Annual General Meeting of Shareholde...
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decide...
WINFARM : Modalités de mise à disposition du Rapport Financier Annuel ...
WINFARM : Modalités de mise à disposition du Rapport Financier Annuel 2024. COMMUNIQUE DE PRESSE Loudéac, le 30 avril 2025 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2024 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier annuel 2024 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 30 avril 2025. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disposition au siège...
WINFARM : Ongoing sales momentum in Q1 2025 with +7.9% growth.
WINFARM : Ongoing sales momentum in Q1 2025 with +7.9% growth. PRESS RELEASE Loudéac, April 29, 2025 Ongoing sales momentum in Q1 2025 with +7.9% growth 2025 Outlook: maintained strong sales momentum and expected improvement in results WINFARM (ISIN: FR0014000P11 – Ticker: ALWF), the leading French player in the supply of consulting, services and distance-selling of products and solutions for the agricultural and livestock industry, is today releasing its revenue figures for the first quarter of 2025. In millions of euros, unauditedQ1 2024Q1 2025ChangeFarming Supplies29.931.5+5.3%Fa...
WINFARM : Poursuite de la dynamique commerciale au 1 er trimestre 2025...
WINFARM : Poursuite de la dynamique commerciale au 1 er trimestre 2025 avec une croissance de +7,9%. COMMUNIQUE DE PRESSE Loudéac, 29 avril 2025 Poursuite de la dynamique commerciale au 1er trimestre 2025 avec une croissance de +7,9% Perspectives 2025 : Maintien d’une forte impulsion commerciale et amélioration attendue des résultats WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chi...
Pharming Group announces upcoming presentations at the 2025 Annual Mee...
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3K...
Pharming receives positive recommendation from NICE for Joenja®▼(lenio...
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive f...
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la fort...
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la forte hausse de la demande sur la zone APAC. COMMUNIQUE DE PRESSE Loudéac, 15 avril 2025 IMPLANTATION D’ALPHATECH A SINGAPOUR POUR REPONDRE A LA FORTE HAUSSE DE LA DEMANDE SUR LA ZONE APAC WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce l’ouverture de sa filiale Alphatech APAC à Singapour. Cette implantation, va permettre à la Société de mieux répondre à l’explosion de la demande sur cette zone stratégique à très fort potentiel. Avec cette nouv...
Pharming Group announces the filing of its 2024 Annual Report and Form...
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found und...
WINFARM : 2024 full-year results and 2025 outlook.
WINFARM : 2024 full-year results and 2025 outlook. PRESS RELEASE Loudéac, 31 March 2025 2024 FULL-YEAR RESULTS Significant improvement in H2 2024 on revenue and EBITDA, in line with targets Solid annual gross margin and positive operating profitability in 2024despite a difficult environment 2025 OUTLOOK Build on H2 2024 momentum to pursue revenue growth Rigorous financial discipline to improve EBITDA Continue reduction of Group debt WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the number one French distance seller for the farming industry, today release its consolidated 2024 ful...
WINFARM : Résultats annuels 2024 et perspectives 2025.
WINFARM : Résultats annuels 2024 et perspectives 2025. COMMUNIQUE DE PRESSE Loudéac, 31 mars 2025 RESULTATS ANNUELS 2024 Deuxième semestre 2024 en nette amélioration en termes de chiffre d’affaires et d’EBITDA conformément aux objectifs fixés Bonne tenue de la marge brute annuelle et rentabilité opérationnelle positive en 2024malgré un contexte difficile PERSPECTIVES 2025 Capitaliser sur la dynamique du 2ème semestre pour poursuivre une croissance du chiffre d’affaires Discipline financière stricte favorisant l’amélioration de l’EBITDA Poursuite du désendettement du Groupe WINFA...
- Michael B. Schäfer
- Michael B. Schäfer
- Christophe Chaput
- Christophe Chaput
Pharming Group announces first patient dosed in Phase II clinical tria...
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.